WINTON GROUP Ltd Sells 5,531 Shares of Axcelis Technologies, Inc. $ACLS

WINTON GROUP Ltd decreased its position in Axcelis Technologies, Inc. (NASDAQ:ACLS) by 39.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,620 shares of the semiconductor company’s stock after selling 5,531 shares during the period. WINTON GROUP Ltd’s holdings in Axcelis Technologies were worth $1,633,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. REAP Financial Group LLC bought a new stake in Axcelis Technologies during the 4th quarter valued at $25,000. EverSource Wealth Advisors LLC grew its position in shares of Axcelis Technologies by 145.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 451 shares of the semiconductor company’s stock worth $31,000 after buying an additional 267 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Axcelis Technologies during the third quarter valued at $32,000. Leonteq Securities AG purchased a new position in shares of Axcelis Technologies during the fourth quarter valued at $40,000. Finally, Clearstead Advisors LLC increased its stake in shares of Axcelis Technologies by 197.1% during the fourth quarter. Clearstead Advisors LLC now owns 719 shares of the semiconductor company’s stock valued at $58,000 after buying an additional 477 shares during the period. Institutional investors own 89.98% of the company’s stock.

Axcelis Technologies Price Performance

Shares of ACLS stock opened at $113.43 on Friday. Axcelis Technologies, Inc. has a 1-year low of $73.60 and a 1-year high of $193.78. The stock’s 50-day moving average is $129.64 and its 200 day moving average is $130.43. The company has a market cap of $3.50 billion, a P/E ratio of 38.06, a PEG ratio of 3.47 and a beta of 1.86. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.90 and a quick ratio of 3.21.

Axcelis Technologies (NASDAQ:ACLS) last announced its earnings results on Thursday, August 6th. The semiconductor company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.17. The business had revenue of $215.18 million during the quarter, compared to the consensus estimate of $205.03 million. Axcelis Technologies had a net margin of 10.71% and a return on equity of 11.69%. The firm’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.13 earnings per share. Axcelis Technologies has set its Q3 2026 guidance at 1.110-1.110 EPS. Research analysts predict that Axcelis Technologies, Inc. will post 3.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ACLS. Craig Hallum lowered shares of Axcelis Technologies from a “buy” rating to a “hold” rating and set a $140.00 price objective for the company. in a research note on Friday, August 7th. Bank of America raised their target price on shares of Axcelis Technologies from $130.00 to $156.00 and gave the company an “underperform” rating in a research report on Tuesday, June 23rd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Axcelis Technologies in a report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $132.20.

Axcelis Technologies Profile

Axcelis Technologies, Inc is a semiconductor equipment company that designs, manufactures and services ion implantation systems used in the production of semiconductor devices. Its equipment modifies the electrical properties of silicon wafers by implanting precisely controlled ions, an important step in manufacturing power semiconductors, memory products and other integrated circuits.

The company’s primary product family is the Purion platform, which includes systems designed for high-current, medium-current and high-energy implantation applications.